A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-09-03) →
What happened
Adbiotech updated the terms of convertible bonds to raise US$4.01M, about 8.7% of its market value.
For context, this raise equals about 8.7% of the company's market value, which is the rough scale of potential new-share dilution.
| Instrument | Convertible bonds |
|---|---|
| Raise amount | US$4.01M |
| vs. market value | 8.7% |
| Filed | 2026-09-01, [Amended] Material event report (convertible bonds) |
| Source | DART rcept 20260901000242 → open original filing |
Versions of this filing
- 2026-06-26Original
- 2026-07-21Amendment 1
- 2026-08-13Amendment 2
- 2026-08-19Amendment 3
- 2026-08-21Amendment 4
- 2026-09-01Amendment 5 (this page)
- 2026-09-03Amendment 6
Source: DART. Information only, not investment advice.